345 related articles for article (PubMed ID: 32409982)
1. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
[TBL] [Abstract][Full Text] [Related]
2. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
3. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects.
Crockett J; Critchley D; Tayo B; Berwaerts J; Morrison G
Epilepsia; 2020 Feb; 61(2):267-277. PubMed ID: 32012251
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy.
Ben-Menachem E; Gunning B; Arenas Cabrera CM; VanLandingham K; Crockett J; Critchley D; Wray L; Tayo B; Morrison G; Toledo M
CNS Drugs; 2020 Jun; 34(6):661-672. PubMed ID: 32350749
[TBL] [Abstract][Full Text] [Related]
5. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
Tayo B; Taylor L; Sahebkar F; Morrison G
Clin Pharmacokinet; 2020 Jun; 59(6):747-755. PubMed ID: 31802404
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam.
VanLandingham KE; Crockett J; Taylor L; Morrison G
J Clin Pharmacol; 2020 Oct; 60(10):1304-1313. PubMed ID: 32652616
[TBL] [Abstract][Full Text] [Related]
7. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
8. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy.
Birnbaum AK; Karanam A; Marino SE; Barkley CM; Remmel RP; Roslawski M; Gramling-Aden M; Leppik IE
Epilepsia; 2019 Aug; 60(8):1586-1592. PubMed ID: 31247132
[TBL] [Abstract][Full Text] [Related]
9. Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects.
Liu X; Xue L; Zhang H; Xu Q; Zhang S; Ma S; Ding X; Liu L; Dong J; Qian L; Xia W; Jiang K; Huang C; Miao L
Clin Drug Investig; 2020 Jun; 40(6):555-566. PubMed ID: 32277364
[TBL] [Abstract][Full Text] [Related]
10. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.
Morrison G; Crockett J; Blakey G; Sommerville K
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1009-1031. PubMed ID: 30791225
[TBL] [Abstract][Full Text] [Related]
11. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
12. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Devinsky O; Patel AD; Thiele EA; Wong MH; Appleton R; Harden CL; Greenwood S; Morrison G; Sommerville K;
Neurology; 2018 Apr; 90(14):e1204-e1211. PubMed ID: 29540584
[TBL] [Abstract][Full Text] [Related]
13. Safety, Tolerability, and Pharmacokinetic Study of 101BHG-D01 Nasal Spray, a Novel Long-Acting and Selective Cholinergic M Receptor Antagonist, in Healthy Chinese Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, First-In-Human Study.
Chu NN; Huang K; Que LL; Ding Y; Gu XH; Zhang L; Wang JK; Chen XP; Sun ZG; He Q
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):509-521. PubMed ID: 35429285
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
15. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
[TBL] [Abstract][Full Text] [Related]
16. A pilot safety, tolerability and pharmacokinetic study of an oro-buccal administered cannabidiol-dominant anti-inflammatory formulation in healthy individuals: a randomized placebo-controlled single-blinded study.
Vitetta L; Butcher B; Henson JD; Rutolo D; Hall S
Inflammopharmacology; 2021 Oct; 29(5):1361-1370. PubMed ID: 34357480
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects.
Vernillet L; Greene SA; Kamin M
Clin Pharmacol Drug Dev; 2020 May; 9(4):428-443. PubMed ID: 32087001
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
[TBL] [Abstract][Full Text] [Related]
19. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
